<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870181</url>
  </required_header>
  <id_info>
    <org_study_id>2009HGG-01</org_study_id>
    <nct_id>NCT00870181</nct_id>
  </id_info>
  <brief_title>ADV-TK Improves Outcome of Recurrent High-Grade Glioma</brief_title>
  <acronym>HGG-01</acronym>
  <official_title>Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for
      patients with these tumors remains poor despite advances in diagnosis and standard therapies
      such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy
      highlight its efficacy and safety for glioma patients. This clinical trial was conducted to
      assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of
      replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV
      administration in patients with recurrent high-grade glioma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point was 6-month progression-free survival rate (PFS-6)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>1. at the time during treatments; 2. at 6-month; 3. at the end of 1-year following-up; 4. at the end of 2-year following up; 5. at the time the patient censored.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit</measure>
    <time_frame>at the end of 2nd ADK-TK/GCV therapy</time_frame>
    <description>the rate of complete response, plus partial response, plus stable disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Malignant Glioma of Brain</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>ADV-TK/GCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received surgery or systemic chemotherapy or palliative care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADV-TK/GCV</intervention_name>
    <description>gene therapy</description>
    <arm_group_label>ADV-TK/GCV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>systemic chemotherapy</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed WHO grades 3 to 4 malignant glioma

          -  Diagnosed recurrence or progression by clinical or radiological evidence

          -  Fit for intraarterial infusion and intravenous chemotherapy

          -  Adequate hepatic, renal, and hematologic function.

          -  Legal age ≥18 years

          -  Life expectancy ≥12 weeks

          -  Eastern Cooperative Oncology Group performance (ECOG) ≥2

          -  Chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities.

        Exclusion Criteria:

          -  Active pregnancy

          -  Prior gene therapy

          -  Second primary tumor

          -  Gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active
             uncontrolled infections

          -  Requiring treatment with warfarin or any other anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ma Ding, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tongji Hospital of HUST</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing YouAn Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>June 22, 2013</last_update_submitted>
  <last_update_submitted_qc>June 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of Department of Gynecology and Obstetrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

